|
Semprex-D (Acrivastine/Pseudoephedrine HCl) Capsules
|
|
Respiratory agent
|
|
Upper respiratory combination
|
|
Runny nose and congestion
|
|
Adults: 1 capsule every 4 to 6 hours, max 4 capsules/day. Children: not recommended.
|
|
Category B
|
|
Drowsiness, Palpitations, headache, Hypertension, dizziness, GI disturbances, nervousness, weakness, trouble sleeping, thickening of bronchial secretion, urinary retention, tremor, Convulsions
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
|
|
|